Similarly, ‘MDS/MPN-RS-T-like’ patients displayed a median percentage of RS higher than the other groups and, clinically, behaved similarly to MDS/MPN-RS-T patients, suggesting that it might be worth considering taking the presence of SF3B1 mutations into account in patients with 5–15% of ring sideroblasts, as in MDS-RS. The gene discussed is SF3B1; the disease is myeloproliferative neoplasm.